An alternative form of melarsoprol in sleeping sickness: Is an old drug always the best basis for a new one?

Trends in Parasitology

Volumn 28, Issue 9, 2012, Pages 354-355

  Burri, Christian ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; EFLORNITHINE; MELARSOPROL; NIFURTIMOX;

AFRICAN TRYPANOSOMIASIS; CLINICAL RESEARCH; DRUG FORMULATION; HEALTH CARE ACCESS; HUMAN; LETTER; PATHOGENESIS; RISK BENEFIT ANALYSIS; TRYPANOSOMA BRUCEI; WORLD HEALTH ORGANIZATION;

ANIMALS; HUMANS; MELARSOPROL; TRYPANOCIDAL AGENTS;

EID: 84865174160     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2012.06.002     Document Type: Letter

References (4)

1. Rodgers J., et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl. Trop. Dis. 2011, 5:e1308.
2. Kennedy P.G.E. An alternative form of melarsoprol in sleeping sickness. Trends Parasitol. 2012, 28:307-310.
3. Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success?. Parasitology 2010, 137:1987-1994.
4. Simarro P.P., et al. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 2012, 139:842-846.